Ultragenyx Pharmaceutical (RARE) EBITDA Margin Growth (3y) (2019 - 2026)
Ultragenyx Pharmaceutical (RARE) EBITDA Margin Growth (3y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -377.00 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -204.00 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 828,504.00 |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7,261.00 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -7.76 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -2,649.00 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 9,003.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 30,461.00 |
| 10 | Ultragenyx Pharmaceutical | 2.61 Bn | 2.33 Bn | 180.00 Mn | 10,156.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10,156.00 |
| Mar 31, 2026 | 2,908.00 |
| Dec 31, 2025 | 8,626.00 |
| Sep 30, 2025 | 14,128.00 |
| Jun 30, 2025 | 9,368.00 |
| Mar 31, 2025 | 6,805.00 |
| Dec 31, 2024 | 4,871.00 |
| Sep 30, 2024 | 1,540.00 |
| Jun 30, 2024 | 1,603.00 |
| Mar 31, 2024 | -4,471.00 |
| Dec 31, 2023 | 913.00 |
| Sep 30, 2023 | -8,622.00 |
| Jun 30, 2023 | -3,443.00 |
| Mar 31, 2023 | 17,898.00 |
| Dec 31, 2022 | 12,446.00 |
| Sep 30, 2022 | 20,936.00 |
| Jun 30, 2022 | 30,727.00 |
| Mar 31, 2022 | 37,504.00 |
| Dec 31, 2021 | 43,257.00 |
| Sep 30, 2021 | 65,208.00 |